The effect of gabapentin on oxidative stress in a model of toxic demyelination in rat brain

Journal of Basic and Clinical Physiology and Pharmacology

Volumn 23, Issue 2, 2012, Pages 61-68

  Abdel Salam, Omar M E ^a   Khadrawy, Yasser Ashry ^a   Mohammed, Nadia A ^a   Youness, Eman R ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Ethidium bromide; Gabapentin; Rat brain; Toxic demyelination

Indexed keywords

ACETYLCHOLINESTERASE; ARYLDIALKYLPHOSPHATASE; ETHIDIUM BROMIDE; GABAPENTIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NITRITE; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEMYELINATING DISEASE; DOSE RESPONSE; DRUG EFFECT; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; RAT;

AMINES; ANIMALS; ANTIOXIDANTS; CEREBRAL CORTEX; CYCLOHEXANECARBOXYLIC ACIDS; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHIDIUM; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84867785416     PISSN: 07926855     EISSN: 21910286     Source Type: Journal    
DOI: 10.1515/jbcpp-2012-0004     Document Type: Article

References (78)

1. Morris GL. Gabapentin. Epilepsia 1999;40:(Suppl 5):S63-70.
2. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002;57:451-62.
3. Ho KY, Gan TJ, Habib AS. Gabapentin and postoperative pain - a systematic review of randomized controlled trials. Pain 2006; 126:91-101.
4. Gordh TE, Stubhaug A, Jensen TS, Arnèr S, Biber B, Boivie J, et al. Gabapentin in traumatic nerve injury pain: a randomized, double-blind, placebo-controlled, cross-over, multi-center study. Pain 2008;138:255-66.
5. Petroianu G, Schmitt A. First line symptomatic therapy for painful diabetic neuropathy: a tricyclic antidepressant or gabapentin ? Int J Diabetes Metab 2002;10:1-13.
6. Bertrand S, Ng GY, Purisai MG, Wolfe SE, Severidt MW, Nouel D, et al. The anticonvulsant, antihyperalgesic agent gabapentin is an agonist at brain gamma-aminobutyric acid type B receptors negatively coupled to voltage-dependent calcium channels. J Pharmacol Exp Ther 2001;298:15-24.
7. Lanneau C, Green A, Hirst WD, Wise A, Brown JT, Donnier E, et al. Gabapentin is not a GABAB receptor agonist. Neuropharmacology 2001;41:965-75.
8. Pöllmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs 2008;22:291-324.
9. Solaro C, Messmer Uccelli M. Pharmacological management of pain in patients with multiple sclerosis. Drugs 2010;70:1245-54.
10. Kitzman PH, Uhl TL, Dwyer MK. Gabapentin suppresses spasticity in the spinal cord-injured rat. Neuroscience 2007;149:813-21.
11. Starck M, Albrecht H, Pöllmann W, Dieterich M, Straube A. Acquired pendular nystagmus in multiple sclerosis: an examinerblind cross-over treatment study of memantine and gabapentin. J Neurol 2010;257:322-7.
12. Traa BS, Mulholland JD, Kadam SD, Johnston MV, Comi AM. Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 2008;64:81-5.
13. Kale A, Börcek A Ö, Emmez H, Yildirim Z, Durdaǧ E, Lortlar N, et al. Neuroprotective effects of gabapentin on spinal cord ischemia-reperfusion injury in rabbits. J Neurosurg Spine 2011;15:228-37.
14. Abdel-Salam OM, Sleem AA. Study of the analgesic, anti- inflammatory, and gastric effects of Gabapentin. Drug Discov Ther 2009;3:18-26.
15. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29:233-49.
16. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39:95-9.
17. Petroff OA, Hyder F, Rothman DL, Mattson RH. Effects of gabapentin on brain GABA, homocarnosine, and pyrrolidinone in epilepsy patients. Epilepsia 2000;41:675-80.
18. Jin Z, Mendu SK, Birnir B. GABA is an effective immunomodulatory molecule. 2011 [Epub ahead of print] DOI: 10.1007/s00726-011-1193-7.
19. Magnaghi V, Ballabio M, Camozzi F, Colleoni M, Consoli A, Gassmann M, et al. Altered peripheral myelination in mice lacking GABAB receptors. Mol Cell Neurosci 2008;37:599-609.
20. Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999;9:69-92.
21. Fischer MT, Sharma R, Lim JL, Haider L, Frischer JM, Drexhage J, et al. NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012;135:886-99.
22. Zeis T, Probst A, Steck AJ, Stadelmann C, Brück W, Schaeren-Wiemers N. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol 2009;19:459-66.
23. Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain 2011;134:1914-24.
24. Besler HT, Comoǧlu S, Okçu Z. Serum levels of antioxidant vitamins and lipid peroxidation in multiple sclerosis. Nutr Neurosci 2002;5:215-20.
25. Koch M, Ramsaransing GS, Arutjunyan AV, Stepanov M, Teelken A, Heersema DJ, et al. Oxidative stress in serum and peripheral blood leukocytes in patients with different disease courses of multiple sclerosis. J Neurol 2006;253:483-7.
26. Choi IY, Lee SP, Denney DR, Lynch SG. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 2011;17:289-96.
27. Carlson NG, Rose JW. Antioxidants in multiple sclerosis: do they have a role in therapy ? CNS Drugs 2006;20:433-41.
28. de Vries HE, Schreibelt G, van Horssen G. Oxidative stress in multiple sclerosis pathology and therapeutic potential of Nrf2 activation. In: Gadoth N, Göbel H, editors. Oxidative stress and free radical damage in neurology. VIII. Springer Science+Business Media, LLC: Humana Press, 2011:65-77.
29. Liñares D, Taconis M, Mañ a P, Correcha M, Fordham S, Staykova M, et al. Neuronal nitric oxide synthase plays a key role in CNS demyelination. J Neurosci 2006;26:12672-81.
30. Yajima K, Suzuki K. Demyelination and remyelination in the rat central nervous system following ethidium bromide injection. Lab Invest 1979;41:385-92.
31. Mazzanti CM, Spanevello RM, Pereira LB, Gonçalves JF, Kaizer R, Corrêa M, et al. Acetylcholinesterase activity in rats experimentally demyelinated with ethidium bromide and treated with interferon beta. Neurochem Res 2006;31:1027-34.
32. Abdel-Salam OM, Khadrawy YA, Salem NA, Sleem AA. Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine. Neurochemical Res 2011;36:1062-72.
33. Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids 1994;59:383-8.
34. Ellman GL. Tissue sulfhydryl groups. Arch Biochem 1959;82:70-7.
35. Ellman GL, Courtney KD, Andress V Jr, Feather-Stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharm 1961;7:88-90.
36. Gorun V, Proinov I, Baltescu V, Balaban G, Barzu O. Modified Ellman procedure for assay of cholinesterases in crude enzymatic preparation. Anal Biochem 1978;86:324-6.
37. Moshage H, Kok B, Huizenga JR. Nitrite and nitrate determination in plasma: a critical evaluation. Clin Chem 1995;41: 892-6.
38. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70:158-69.
39. Higashino K, Takahashi Y, Yamamura Y. Release of phenyl acetate esterase from liver microsomes by carbon tetrachloride. Clin Chim Acta 1972;41:313-20.
40. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 1995;96:2882-91.
41. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clinc Chem 1995;41:1819-28.
42. Halliwell B, Gutteridge JM editors. Free radicals in biology and medicine, 2nd ed. Oxford: Clarendon Press, 1989:22-85.
43. Wang W, Ballatori N. Endogenous glutathione conjugates: occurrence and biological functions. Pharmacol Rev 1998;50:335-56.
44. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987;1:358-64.
45. Reiter RJ. Oxidative processes and antioxidative defense mechanisms in the aging brain. FASEB J 1995;9:526-33.
46. Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine. J Neurosci 2000;20:1-7.
47. Lei XG. Glutathione peroxidase-1 gene knockout on body antioxidant defense in mice. Biofactors 2001;14:93-9.
48. Syburra C, Passi S. Oxidative stress in patients with multiple sclerosis. Ukr Biokhim Zh 1999;71:112-5.
49. Tasset I. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012;45:440-4.
50. Costa LG, Cole TB, Vitalone A, Furlong CE. Measurement of paraoxonase (PON1) status as a potential biomarker of susceptibility to organophosphate toxicity. Clin Chim Acta 2005;352:37-47.
51. Furlong CE. Paraoxonases: an historical perspective. In: Mackness B, Mackness M, Aviram M, Paragh G, editors. The paraoxonases: their role in disease development and xenobiotic metabolism. Dordrecht: Springer, 2008:3-31.
52. La Du BN. Human serum paraoxonase: arylesterase. In: Kalow W, editor. Pharmacogenetics of drug metabolism. Elmford, NY: Pergamon, 1992:51-91.
53. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 1996;33:498-507
54. Mackness B, Quarck R, Verreth W, Mackness M, Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:1545-50.
55. Rodrigo L, Hernández AF, López-Caballero JJ, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001;137:123-37.
56. Jamroz-Wisniewska A, Beltowski J, Stelmasiak Z, Bartosik- Psujek H. Paraoxonase 1 activity in different types of multiple sclerosis. Mult Scler 2009;15:399-402.
57. Wehr H, Bednarska-Makaruk M, Graban A, Lipczyńska-Łojkowska W, Rodo M, Bochyńska A, et al. Paraoxonase activity and dementia. J Neurol Sci 2009;283:107-8.
58. Moncada S, Bolaños JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006;97:1676-89.
59. Koppal T, Drake J, Yatin S, Jordan B, Varadarajan S, Bettenhausen L, et al. Peroxynitrite-induced alterations in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J Neurochem 1999;72:310-7.
60. Wei T, Chen C, Hou J, Xin W, Mori A. Nitric oxide induces oxidative stress and apoptosis in neuronal cells. Biochimica et Biophysica Acta 2000;1498:72-9.
61. Steinert JR, Chernova T, Forsythe ID. Nitric oxide signaling in brain function, dysfunction, and dementia. Neuroscientist 2010;16:435-52.
62. Ibragic S, Sofic E, Suljic E, Avdagic N, Bajraktarevic A, Tahirovic I. Serum nitric oxide concentrations in patients with multiple sclerosis and patients with epilepsy. J Neural Transm 2012;119:7-11.
63. Ortiz GG, Macías-Islas MA, Pacheco-Moisés FP, Cruz-Ramos JA, Sustersik S, Barba EA, et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009;26:35-9.
64. Ljubisavljevic S, Stojanovic I, Pavlovic D, Milojkovic M, Vojinovic S, Sokolovic D, et al. Correlation of nitric oxide levels in the cerebellum and spinal cord of experimental autoimmune encephalomyelitis rats with clinical symptoms. Acta Neurobiol Exp (Wars) 2012;72:33-9.
65. Colombo E, Cordiglieri C, Melli G, Newcombe J, Krumbholz M, Parada LF, et al. Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med 2012;209:521-35.
66. Yao SY, Ljunggren-Rose A, Chandramohan N, Whetsell WO Jr, Sriram S. In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes. J Neuroimmunol 2010;229:146-56.
67. Yao SY, Natarajan C, Sriram S. nNOS mediated mitochondrial injury in LPS stimulated oligodendrocytes. Mitochondrion 2012;12:336-44.
68. Gilgun-Sherki Y, Panet H, Melamed E, Offen D. Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Res 2003;989:196-204.
69. Bolton C, Paul C. Glutamate receptors in neuroinflammatory demyelinating disease. Med Inflamm 2006;2006:1-12.
70. Castegna A, Palmieri L, Spera I, Porcelli V, Palmieri F, Fabis- Pedrini MJ, et al. Oxidative stress and reduced glutamine synthetase activity in the absence of inflammation in the cortex of mice with experimental allergic encephalomyelitis. Neuroscience 2011;185:97-105.
71. Kaufer D, Friedman A, Seidman S, Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998;393:373-7.
72. Bond CE, Patel P, Crouch L, Tetlow N, Day T, Abu-Hayyeh S, et al. Astroglia up-regulate transcription and secretion of 'readthrough' acetylcholinesterase following oxidative stress. Eur J Neurosci 2006;24:381-6.
73. Härtl R, Gleinich A, Zimmermann M. Dramatic increase in readthrough acetylcholinesterase in a cellular model of oxidative stress. J Neurochem 2011;116:1088-96.
74. Bond CE, Greenfield SA. Multiple cascade effects of oxidative stress on astroglia. Glia 2007;55:1348-61.
75. Donat CK, Schuhmann MU, Voigt C, Nieber K, Schliebs R, Brust P. Alterations of acetylcholinesterase activity after traumatic brain injury in rats. Brain inj 2007;21:1031-7.
76. Hubbard RE, O'Mahony MS, Calver BL, Woodhouse KW. Plasma esterases and inflammation in ageing and frailty. Eur J Clin Pharmacol 2008;64:895-900.
77. Pavlov VA, Parrish WR, Rosas-Ballina M, Ochani M, Puerta M, Ochani K, et al. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav Immun 2009;23:41-5.
78. Darvesh S, Leblanc AM, Macdonald IR, Reid GA, Bhan V, Macaulay RJ, et al. Butyrylcholinesterase activity in multiple sclerosis neuropathology. Chem Biol Interact 2010;187: 425-31.